Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature‐based analysis was undertaken to assess, via an indirect treatment comparis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaloyannidis, Panayotis, Hertzberg, Mark, Webb, Kate, Zomas, Athanasios, Schrover, Rudolf, Hurst, Michael, Jacob, Ian, Nikoglou, Thalia, Connors, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028067/
https://www.ncbi.nlm.nih.gov/pubmed/31588564
http://dx.doi.org/10.1111/bjh.16201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028067/
https://www.ncbi.nlm.nih.gov/pubmed/31588564
http://dx.doi.org/10.1111/bjh.16201

Ejemplares similares